Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: Thirty-six-month results from the european schizophrenia outpatient health outcomes study

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 531-540

  Novick, Diego ^a,b   Haro, Josep Maria ^c   Bertsch, Jordan ^d   Haddad, Peter M ^e  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d PARC SANITARI SANT JOAN DE DÉU   (Spain)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

antipsychotic treatment; EPS; schizophrenia; TD

Indexed keywords

AMISULPRIDE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOM; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; COHORT STUDIES; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77957267779     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181f14098     Document Type: Article

References (60)

1. Owens DG. Involuntary disorders of movement in chronic schizophreniaVthe role of the illness and its treatment. Psychopharmacology Suppl. 1985;2: 79-87.
2. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Safety. 2005;28: 191-208. (Pubitemid 40364887)
3. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657): 31-41.
4. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21: 911-936. (Pubitemid 47557106)
5. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13: 13-24. (Pubitemid 46148428)
6. Boyer W, Bakalar N, Lake C. Anticholinergic prophylaxis of acute haloperidolYinduced dystonic reactions. J Clin Psychopharmacol. 1987;7: 164-166. (Pubitemid 17111753)
7. Ayd F. A survey of drug-induced extrapyramidal reactions. JAMA. 1961;175: 1054-1060.
8. Sachdev PS. The current status of tardive dyskinesia. Aust NZ J Psychiatry. 2000;34: 355-369.
9. Smith JM, Baldessarini RJ. Changes in prevalence, severity and recovery in tardive dyskinesia with age. Arch Gen Psychiatry. 1980;37: 1368-1373.
10. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161: 414-425. (Pubitemid 38326094)
11. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80: 33-43.
12. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. In: Casey DE, Chase TN, Christensen AV, et al, eds. Dyskinesia Research and Treatment. Berlin, Germany: Springer-Verlag; 1985: 72-78.
13. Kane J, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 1986;22: 254-258. (Pubitemid 16101366)
14. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18: 701-715.
15. Kasper S, Lowry AJ, Hodge A, et al. Tardive dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. Schizophr Res. 2006;81: 139-143. (Pubitemid 43107687)
16. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50: 541-547. (Pubitemid 43161786)
17. Haro JM, Edgell ET, Jones PB, et al. The European Schizophrenia Outpatient Health Outcome (SOHO) study: rationale, methods and recruitment. Acta Psychiatrica Scand. 2003;107: 222-232.
18. Guy W. ECDEUAssessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Mental Health; 1976.
19. Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17: 235-244. (Pubitemid 46164772)
20. Novick D, Haro JM, Suarez D, et al. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology (Berl). 2007;191: 1015-1022. (Pubitemid 46399150)
21. Novick D, Haro JM, Suarez D, et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009;108: 223-230.
22. Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol. 2009;19: 542-550. (Pubitemid 351221254)
23. Brooks R with the EuroQol Group. EuroQol: the current state of play. Health Policy. 1996;37: 53-72.
24. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16: 23-45. (Pubitemid 34151336)
25. Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev. 2006;19(2): CD005237.
26. Chan HY, Chang CJ, Chiang SC, et al. A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism. J Psychopharmacol. 2010;24: 91-98.
27. Kapur S, Seeman P. Does fast dissociation from the dopamine D(2) receptors explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158: 360-369. (Pubitemid 32205190)
28. Chakos MH, Mayerhoff DI, Loebel AD, et al. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull. 1992;28: 81-86.
29. Aguilar EJ, Keshavan MS, Martínez-Quiles MD, et al. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry. 1994;151: 1819-1821. (Pubitemid 24370908)
30. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry. 1999;174: 23-30.
31. Lykouras L, Agelopoulos E, Tzavellas E. Improvement of tardive dyskinesia following switch from neuroleptics to olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26: 815-817. (Pubitemid 34615985)
32. Kinon BJ, Jeste DV, Kollack-Walker S, et al. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28: 985-996. (Pubitemid 39223354)
33. Klawans H, Rubovits R. An experimental model of tardive dyskinesia. J Neural Trans. 1972;33: 235-246.
34. Gunne L, Haggstrom J, Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain: GABA synthesis. Nature. 1984;309: 347-349. (Pubitemid 14145835)
35. Gunne L, Haggstrom J. Pathophysiology of tardive dyskinesia. Psychopharmacology. 1985;232: 191-193.
36. Csernansky JG, Kaplan J, Holman CA, et al. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients. Psychopharmacology (Berl). 1983;81: 115-118. (Pubitemid 13002848)
37. Guy W, Ban TA, Wilson WH. The prevalence of abnormal involuntary movements among chronic schizophrenics. Int Clin Psychopharmacol. 1986;1: 134-144.
38. Barnes TR. A rating scale for drug induced akathisia. Br J Psychiatry. 1989;154: 672-676.
39. Opler LA, Kay SR, Rosado V, et al. Positive and negative syndromes in chronic schizophrenic inpatients. J Nerv Ment Dis. 1984;172: 317-325. (Pubitemid 14079970)
40. Richardson MA, Pass R, Bregman Z, et al. Tardive dyskinesia and depressive symptoms in schizophrenics. Psychopharmacol Bull. 1985;21: 130-135. (Pubitemid 15010892)
41. Tenback DE, van Harten PN, Slooff CJ, et al. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Compr Psychiatry. 2007;48: 436-440.
42. Tenback DE, van Harten PN, Slooff CJ, et al. Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances. Neuropsychopharmacology. 2006;31: 1832-1837. (Pubitemid 44106715)
43. Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: an overview. Am J Psychiatry. 1981;138: 297-309. (Pubitemid 11155876)
44. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959-1979. Arch Gen Psychiatry. 1982;39: 473-481. (Pubitemid 12152816)
45. Waddington JL, Molloy AG. Duration of treatment relationships for involuntary movements (tardive dyskinesia): concordance between cross-sectional, clinical and longitudinal animal studies. Arch Gen Psychiatry. 1986;43: 191-192.
46. Waddington JL, Youssef HA. Late onset involuntary movements in chronic schizophrenia: relationship of tardive dyskinesia to intellectual impairment and negative symptoms. Br J Psychiatry. 1986;149: 616-620.
47. Waddington JL, Youssef HA. An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms. Am J Psychiatry. 1986;143: 1162-1165.
48. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA. 1991;266: 2402-2406.
49. Saltz BL, Kane JM, Woerner MG, et al. Aging and tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV, eds. Neuroleptic-Induced Movement Disorders. Cambridge: Cambridge University Press; 1997: 13-25.
50. Jeste DV, Lacro JP, Palmer B, et al. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry. 1999;156: 309-311. (Pubitemid 29077124)
51. Kane JM, Jeste DV, Barnes TRE, et al. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992.
52. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptics. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993;50: 723-733. (Pubitemid 23141515)
53. Crane GE. Prevention and management of tardive dyskinesia. Am J Psychiatry. 1972;129: 466-467.
54. Chouinard G, Annable L, Mercier P, et al. A five year follow-up study of tardive dyskinesia. Psychopharmacol Bull. 1986;22: 259-263. (Pubitemid 16101367)
55. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 1995;52: 756-765.
56. Woerner MG, Alvir JMJ, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155: 1521-1528. (Pubitemid 28512019)
57. Sachdev P. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Aust N Z J Psychiatry. 2004;38: 445-449. (Pubitemid 39029052)
58. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212: 11-19.
59. Haro JM, Edgell ET, Frewer P, et al. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr Scand. 2003;107(suppl 416): 1-9. (Pubitemid 36683636)
60. Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346: 16-22. (Pubitemid 34438915)